Why MannKind Corporation Popped Today

Shares of MannKind Corporation (NASDAQ: MNKD), a commercial-stage biopharma focused on inhaled insulin, rose as much as 13% in afternoon trading on Monday. Shareholders can largely thank two positive developments for the jump.

First, MannKind announced that the FDA has OK'd an update to Afrezza's prescribing information. Here's a quick review of the labeling update:

Here's what MannKind's CEO Michael Castagna had to say about this labeling change on a special investor call:

Source: Fool.com